| Literature DB >> 33855363 |
S J Tingle1, E R Thompson1, S S Ali2, R Figueiredo1, M Hudson3, G Sen1, S A White1, D M Manas1, C H Wilson1.
Abstract
BACKGROUND: Biliary leaks and anastomotic strictures are common early anastomotic biliary complications (EABCs) following liver transplantation. However, there are no large multicentre studies investigating their clinical impact or risk factors. This study aimed to define the incidence, risk factors and impact of EABC.Entities:
Mesh:
Year: 2021 PMID: 33855363 PMCID: PMC8047096 DOI: 10.1093/bjsopen/zrab019
Source DB: PubMed Journal: BJS Open ISSN: 2474-9842
Fig. 2Impact of early anastomotic biliary complications on patient survival
Each panel is a Kaplan–Meier graph, with numbers at risk displayed. P values are the result of log-rank tests. aP < 0.001. Shaded areas represent 95 per cent confidence intervals. b P < 0.001. cP = 0.637. d P = 0.155
Demographic information for the entire dataset
|
| |
|
| |
|
| |
| Donor age (years) | 50.0 (6–86) |
| Cold ischaemic time (min) | 511.8 (163.5) |
| Donor type | |
| DBD | 6476 (78.0) |
| DCD | 1677 (20.2) |
| Living | 111 (1.3) |
| Domino | 40 (0.5) |
|
| |
| Recipient age (years) | 54.0 (18–75) |
| Recipient MELD | 16.6 (6.84) |
| Biliary anastomosis type | |
| CDCD | 6599 (80.2) |
| Roux-en-Y | 1261 (15.3) |
| T-tube | 330 (4.0) |
| Stent | 40 (0.5) |
|
| |
| No biliary complication | 7505 (90.4) |
| Biliary leak only | 344 (4·14) |
| Biliary stricture only | 335 (4·03) |
| Both leak and stricture | 120 (1·44) |
Values in parentheses are percentages unless indicated otherwise;
values are mean(s.d.);
values are median (range). DBD, donation following brainstem death; DCD, donation following circulatory death; MELD, model for end-stage liver disease; CDCD, choledocho–choledochostomy.
Donor factors associated with early anastomotic biliary complications
| Donor factor |
|
|
|
|
|
|---|---|---|---|---|---|
|
| 50 (6–86) ( | 45 (6–83) | 48 (11–85) | 49.5 (18–79) | 0·001 |
|
| |||||
| Male | 3927 (90·2) | 174 (4·0) | 189 (4·3) | 65 (1·5) | 0·428 |
| Female | 3575 (90·6) | 170 (4·3) | 146 (3·7) | 55 (1·4) | |
|
| 512(162) ( | 522(183), ( | 498(169), ( | 509(189), ( | 0·298 |
|
| 27·0(8·2) ( | 29·0(10·7) ( | 27·6(7·1) ( | 27·9(8·8) ( | 0·536 |
|
| |||||
| DBD | 5887 (90·9) | 264 (4·1) | 245 (3·8) | 80 (1·2) | <0·001 |
| DCD | 1505 (89·7) | 61 (3·6) | 82 (4·9) | 29 (1·7) | |
| Living | 78 (70·3) | 15 (13·5) | 7 (6·3) | 11 (9·9) | |
| Domino | 35 (87·5) | 4 (10·0) | 1 (2·5) | 0 (0) | |
|
| |||||
| No steatosis | 4087 (90·4) | 196 (4·3) | 181 (4·0) | 57 (1·3) | 0·709 |
| Mild | 2302 (90·7) | 98 (3·9) | 104 (4·1) | 35 (1·4) | |
| Moderate | 835 (91·4) | 29 (3·2) | 36 (3·9) | 14 (1·5) | |
| Severe | 72 (93·5) | 1 (1·3) | 4 (5·2) | 0 (0) | |
|
| |||||
| Whole liver | 6926 (91·2) | 267 (3·5) | 307 (4·0) | 95 (1·3) | <0·001 |
| Reduced or split liver | 579 (81·7) | 77 (10·9) | 28 (3·9) | 25 (3·5) | |
|
| |||||
| White | 7028 (90·6) | 309 (4·0) | 308 (4·0) | 109 (1·4) | 0·008 |
| Asian | 160 (89·9) | 8 (4·5) | 8 (4·5) | 2 (1·1) | |
| Black | 106 (91·4) | 4 (3·4) | 4 (3·4) | 2 (1·7) | |
| Other | 150 (80·2) | 18 (9·6) | 14 (7·5) | 5 (2·7) | |
|
| 26·1(4·8) ( | 25·5(4·7) ( | 26·2(5·1) ( |
26·6(4·8) ( | 0·076 |
|
| |||||
| Diabetic | 426 (91·2) | 7 (1·5) | 28 (6·0) | 6 (1·3) | 0·005 |
| Non-diabetic | 6777 (90·6) | 311 (4·2) | 290 (3·9) | 99 (1·3) | |
| Hypertensive | 1916 (91·1) | 67 (3·2) | 98 (4·7) | 23 (1·1) | 0·027 |
| Non-hypertensive | 5221 (90·5) | 249 (4·3) | 217 (3·8) | 81 (1·4) | |
| History of alcohol abuse | 607 (90·7) | 23 (3·4) | 30 (4·5) | 9 (1·3) | 0·669 |
| No alcohol abuse | 4927 (90·8) | 214 (3·9) | 200 (3·7) | 84 (1·5) | |
| CVS disease | 712 (91·6) | 24 (3·1) | 30 (3·9) | 11 (1·4) | 0·549 |
| No CVS disease | 6392 (90·6) | 293 (4·2) | 280 (4·0) | 93 (1·3) | |
| History of liver disease | 82 (83·7) | 8 (8·2) | 6 (6·1) | 2 (2·0) | 0·064 |
| No liver disease | 7036 (90·8) | 305 (3·9) | 310 (4·0) | 102 (1·3) | |
| Smoker | 3715 (90·9) | 169 (4·1) | 153 (3·7) | 49 (1·2) | 0·409 |
| Non-smoker | 3515 (90·6) | 145 (3·7) | 164 (4·2) | 56 (1·4) |
Values in parentheses are percentages unless otherwise indicated. Percentages displayed describe biliary complication rate for each donor factor (within-row percentages).
Values are median (range);
values are mean(s.d.).
χ2 test, except
Monte Carlo simulations of Fishers exact test,
one-way ANOVA. Raw data are given, a summary of missing data is found in . Further donor factors are displayed in .
Recipient factors associated with early anastomotic biliary complications
| Recipient factor | No biliary complication ( |
|
|
|
|
|---|---|---|---|---|---|
|
| 54 (17–75) | 54 (17–73) | 53 (19–73) | 55 (20–72) | 0·224 |
|
| |||||
| Male | 4675 (90·8) | 196 (3·8) | 197 (3·8) | 83 (1·6) | 0·045 |
| Female | 2829 (89·8) | 148 (4·7) | 138 (4·4) | 37 (1·2) | |
|
| |||||
| Non-biliary | 6185 (90·5) | 267 (3·9) | 285 (4·2) | 97 (1·4) | 0·013 |
| PBC | 600 (88·2) | 36 (5·3) | 35 (5·1) | 9 (1·3) | |
| PSC | 692 (91·4) | 39 (5·2) | 14 (1·8) | 12 (1·6) | |
| Biliary atresia | 28 (84·8) | 2 (6·1) | 1 (3·0) | 2 (6·1) | |
|
| 910 (91·1) | 37 (3·7) | 42 (4·2) | 10 (1·0) | 0·527 |
| Not listed as super-urgent | 6595 (90·3) | 307 (4·2) | 293 (4·0) | 110 (1·5) | |
|
| |||||
| Not acute | 6335 (90·4) | 288 (4·1) | 275 (3·9) | 106 (1·5) | 0·022 |
| Hyperacute | 618 (92·9) | 22 (3·3) | 18 (2·7) | 7 (1·1) | |
| Acute | 224 (89·2) | 8 (3·2) | 17 (6·8) | 2 (0·8) | |
| Subacute | 148 (87·1) | 10 (5·9) | 12 (7·1) | 0 | |
|
| 16·6(6·8) ( | 17·7(7·5) ( | 16·2(6·8) ( | 16·5(7·3) ( | 0·048 |
Values in parentheses are percentages unless indicated otherwise. Percentages displayed describe biliary complication rate for each recipient factor (within-row percentages).
Values are median (range);
values are mean(s.d.).
χ2 test, except
Monte Carlo simulations of Fishers exact test,
one-way ANOVA. Raw data are given, a summary of missing data is found in . Further recipient factors are displayed in . PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; MELD, model for end-stage liver disease.
Operative factors associated with early anastomotic biliary complications
| Operative factor |
|
|
|
|
|
|---|---|---|---|---|---|
|
| |||||
| 2006–2009 | 2034 (91·3) | 99 (4·4) | 67 (3·0) | 27 (1·2) | 0·086 |
| 2010–2013 | 2357 (89·9) | 103 (3·9) | 119 (4·5) | 44 (1·7) | |
| 2014–2017 | 3114 (90·2) | 142 (4·1) | 149 (4·3) | 49 (1·4) | |
|
| |||||
| CDCD | 5967 (90·4) | 235 (3·6) | 291 (4·4) | 106 (1·6) | <0·001 |
| Roux | 1153 (91·4) | 70 (5·6) | 27 (2·1) | 11 (0·9) | |
| T-tube | 282 (85·5) | 34 (10·3) | 12 (3·6) | 2 (0·6) | |
| Stent | 35 (87·5) | 4 (10) | 1 (2·5) | 0 | |
|
| |||||
| Single | 4997 (90·2) | 218 (3·9) | 238 (4·3) | 87 (1·6) | 0·114 |
| Accessory | 1222 (88·2) | 71 (5·1) | 71 (5·1) | 22 (1·6) | |
|
| |||||
| Single | 5255 (89·9) | 238 (4·1) | 258 (4·4) | 93 (1·6) | 0·831 |
| Multiple | 860 (89·1) | 45 (4·7) | 45 (4·7) | 15 (1·6) | |
|
| 39 (10–217) ( | 41 (17–181) ( | 38 (13–95) ( | 42 (13–102) ( | 0·002 |
Values in parentheses are percentages unless indicated otherwise. Percentages displayed describe biliary complication rate for each operative factor (within-row percentages).
Values are median (range).
χ2 test, except
Monte Carlo simulations of Fishers exact test,
Kruskall–Wallis test. Raw data are given, a summary of missing data is found in . CDCD, choledocho-choledochostomy, Roux, Roux-en-Y hepaticojejunostomy; HA, hepatic artery.
Early postoperative complications (within 3 months) associated with early anastomotic biliary complications
| Postoperative factor |
|
|
|
|
|
|---|---|---|---|---|---|
|
| |||||
| 0 | 6160 (91·1) | 257 (3·8) | 255 (3·8) | 91 (1·3) | <0·001 |
| 1 | 1055 (89·0) | 63 (5·3) | 48 (4·0) | 20 (1·7) | |
| ≥2 | 212 (80·6) | 21 (8·0) | 25 (9·5) | 5 (1·9) | |
|
| |||||
| Nil | 5956 (90·7) | 256 (3·9) | 256 (3·9) | 100 (1·5) | 0·002 |
| Transient filtration | 870 (90·4) | 46 (4·8) | 37 (3·8) | 9 (0·9) | |
| Short-term dialysis | 571 (88·4) | 31 (4·8) | 34 (5·3) | 10 (1·5) | |
| Long-term dialysis | 21 (67·7) | 6 (19·4) | 3 (9·7) | 1 (3·2) | |
|
| 233 (82·9) | 30 (10·7) | 11 (3·9) | 7 (2·5) | <0·001 |
| No HA thrombus | 7272 (90·7) | 314 (3·9) | 324 (4·0) | 111 (1·4) | |
|
| 227 (87·6) | 13 (5·0) | 13 (5·0) | 6 (2·3) | 0·410 |
| No PV thrombus | 7278 (90·5) | 330 (4·1) | 322 (4·0) | 112 (1·4) | |
|
| 583 (82·7) | 63 (8·9) | 51 (7·2) | 8 (1·1) | <0·001 |
| No CMV infection | 6900 (91·1) | 280 (3·7) | 284 (3·7) | 111 (1·5) | |
|
| 147 (79·9) | 25 (13·6) | 8 (4·3) | 4 (2·2) | <0·001 |
| No fungal infection | 7335 (90·6) | 317 (3·9) | 326 (4·0) | 116 (1·4) | |
|
| 2467 (84·9) | 217 (7·5) | 173 (6·0) | 50 (1·7) | <0·001 |
| No sepsis | 4997 (93·4) | 127 (2·4) | 160 (3·0) | 68 (1·3) |
Values in parentheses are percentages. Percentages displayed describe biliary complication rate for each postoperative factor (within-row percentages).
χ2 test, except
Monte Carlo simulations of Fishers exact test. Raw data are given, a summary of missing data is found in . RRT, renal replacement therapy; HA, hepatic artery; PV, portal vein; CMV, cytomegalovirus.
Outcomes at 1-year separated by biliary complication
| Outcomes at 1-year |
|
|
|
|
|
|---|---|---|---|---|---|
|
| 15 (4–378) ( | 26 (7–119) ( | 20·5 (6–108) ( | 26 (8–402) ( | <0·001 |
|
| |||||
| 0 | 4195 (67·6) | 127 (46·5) | 114 (42·5) | 41 (40·2) | <0·001 |
| 1 | 1143 (18·4) | 70 (25·6) | 67 (25·0) | 22 (21·6) | |
| >1 | 870 (14) | 76 (27·8) | 87 (32·5) | 39 (38·2) | |
|
| 1393 (22·8) | 55 (20·3) | 75 (28·4) | 16 (16) | 0·040 |
| No renal dysfunction | 4729 (77·2) | 216 (79·7) | 189 (71·6) | 84 (84) | |
|
| |||||
| Bilirubin (μmol/l) | 10 (1–977) ( | 10 (3–790) ( | 10 (2–676) ( | 10 (3–455) ( | 0·344 |
| ALP (unit/l) | 126 (10–1995) ( | 140·5 (11–1917) ( | 168·5 (44–1306) ( | 205 (9–1749) ( | <0·001 |
| ALT (unit/l) | 26 (3–1371) ( | 28 (6–1238) ( | 27 (6–332) ( | 37·5 (8–274) ( | 0·045 |
| AST (unit/l) | 23 (2–1814) ( | 27 (6–780) ( | 27 (8–2219) ( | 38 (13–179) ( | 0·001 |
Values in parentheses are percentages except where indicated otherwise. Percentages represent the chances of renal dysfunction or readmission in each of the biliary complication groups (within column percentage).
Values are median (range).
χ2 test, except
Kruskall-Wallis test. ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase.
Graft survival Cox regression using pooled data from all 20 imputed datasets (n = 8304 per imputation).
| Univariable | Adjusted | |||
|---|---|---|---|---|
| Variable | Hazard ratio |
|
|
|
| ; | ||||
| None | 1 | – | 1 | – |
| Leak only | 1·761 (1·398–2·217) | <0·001 | 1·344 (1·059–1·705) | 0·015 |
| Stricture only | 1·571 (1·220–2·023) | <0·001 | 1·513 (1·171–1·956) | 0·002 |
| Leak plus stricture | 1·726 (1·169–2·547) | 0·006 | 1·526 (1·028–2·264) | 0·036 |
|
| ||||
| Non-biliary | 1 | – | 1 | – |
| Primary biliary cirrhosis | 0·796 (0·633–1·002) | 0·052 | 0·868 (0·687–1·098) | 0·238 |
| Primary sclerosing cholangitis | 1·517 (1·277–1·802) | <0·001 | 1·624 (1·356–1·943) | <0·001 |
| Biliary atresia | 1·918 (0·956–3·847) | 0·067 | 2·126 (1·050–4·302) | 0·036 |
|
| ||||
| Not acute | 1 | 1 | ||
| Hyperacute | 0·905 (0·730–1·121) | 0·362 | 0·710 (0·549–0·917) | 0·009 |
| Acute | 1·241 (0·923–1·669) | 0·152 | 1·310 (0·958–1·793) | 0·091 |
| Subacute | 0·653 (0·405–1·055) | 0·082 | 0·751 (0·461–1·223) | 0·250 |
|
| 0·987 (0·968–1·006) | 0·190 | 0·960 (0·941–0·980) | <0·001 |
|
| ||||
| Whole | 1 | 1 | ||
| Reduced | 0·789 (0·457–1·364) | 0·397 | 0·801 (0·199–3·229) | 0·755 |
| Split | 1·149 (0·936–1·411) | 0·184 | 1·642 (1·299–2·075) | <0·001 |
|
| ||||
| DBD | 1 | 1 | ||
| DCD | 1·460 (1·273–1·675) | <0·001 | 1·818 (1·557–2·122) | <0·001 |
| Living | 0·963 (0·531–1·746) | 0·902 | 1·559 (0·337–7·216) | 0·570 |
| Domino | 1·793 (0·930–3·458) | 0·081 | 2·914 (1·497–5·673) | 0·002 |
|
| ||||
| 0 | 1 | 1 | ||
| 1 | 3·173 (1·702–5·913) | <0·001 | 4·113 (2·047–8·262) | <0·001 |
| 2 | 4·783 (0·673–33·992) | 0·110 | 6·723 (0·936–48·306) | 0·058 |
|
| ||||
| 0 | 1 | 1 | ||
| 1 | 1·648 (1·379–1·970) | <0·001 | 1·802 (1·485–2·100) | <0·001 |
| >1 | 2·616 (1·785–3·834) | <0·001 | 3·753 (2·540–5·545) | <0·001 |
|
| 1·007 (1·003–1·010) | <0·001 | 1·013 (1·009–1·017) | <0·001 |
|
| 1·361 (1·088–1·703) | 0·007 | 1·480 (1·181–1·855) | 0·001 |
|
| 1·147 (1·021–1·287) | 0·021 | 1·196 (1·061–1·348) | 0·003 |
|
| 1·004 (1·000–1·007) | 0·041 | 1·005 (1·001–1·009) | 0·015 |
|
| ||||
| 0 | 1 | 1 | ||
| 1 | 1·123 (0·961–1·311) | 0·145 | 1·189 (1·014–1·394) | 0·033 |
| >1 | 1·379 (1·051–1·809) | 0·020 | 1·381 (1·049–1·818) | 0·021 |
|
| ||||
| Nil | 1 | 1 | ||
| Transient filtration | 1·802 (1·536–2·113) | <0·001 | 1·907 (1·599–2·273) | <0·001 |
| Short-term dialysis | 2·448 (2·069–2·898) | <0·001 | 2·430 (2·039–2·896) | <0·001 |
| Long-term dialysis | 4·460 (2·473–8·043) | <0·001 | 3·551 (1·915–6·585) | <0·001 |
|
| 12·212 (10·433–14·296) | <0·001 | 10·749 (9·122–12·665) | <0·001 |
|
| 2·025 (1·493–2·748) | <0·001 | 1·484 (1·086–2·029) | 0·013 |
Values in parentheses are 95 per cent confidence intervals. These variables were selected using a backwards stepwise approach. Interaction term between previous liver and non-liver transplants included in model but not displayed. DBD, donation following brainstem death; DCD, donation following circulatory death; CIT, cold ischaemic time, RRT, renal replacement therapy; HA, hepatic artery.
Patient survival Cox regression using pooled data from all 20 imputed datasets (n = 8063 per imputation)
| Univariable | Adjusted | |||
|---|---|---|---|---|
| Variable | Hazard ratio | P | Hazard ratio | P |
|
| ||||
| None | 1 | 1 | ||
| Leak only | 1·406 (1·098–1·799) | 0·007 | 1·215 (0·941–1·568) | 0·136 |
| Stricture only | 1·523 (1·186–1·957) | 0·001 | 1·526 (1·183–1·968) | 0·001 |
| Leak plus stricture | 1·579 (1·062–2·347) | 0·024 | 1·509 (1·013–2·248) | 0·043 |
|
| ||||
| Non-biliary | 1 | 1 | ||
| Primary biliary cirrhosis | 0·773 (0·621–0·962) | 0·021 | 0·754 (0·604–0·940) | 0·012 |
| Primary sclerosing cholangitis | 0·900 (0·733–1·104) | 0·310 | 0·988 (0·804–1·215) | 0·910 |
| Biliary atresia | 0·789 (0·296–2·107) | 0·637 | 1·473 (0·582–3·728) | 0·443 |
|
| 1·021 (1·015–1·026) | <0·001 | 1·025 (1·019–1·030) | <0·001 |
|
| 0·957 (0·938–0·977) | <0·001 | 0·937 (0·918–0·957) | <0·001 |
|
| ||||
| 0 | 1 | 1 | ||
| 1 | 2·737 (1·366–5·487) | 0·005 | 1·592 (0·765–3·312) | 0·214 |
| 2 | 5·348 (0·752–38·014) | 0·094 | 10·094 (3·702–27·520) | 0·021 |
|
| ||||
| 0 | 1 | 1 | ||
| 1 | 0·603 (0·453–0·802) | 0·001 | 0·520 (0·386–0·700) | <0·001 |
| 2 | 0·941 (0·470–1·887) | 0·865 | 1·176 (0·603–2·294) | 0·650 |
| >2 | 3·723 (1·395–9·938) | 0·009 | 6·195 (2·918–13·154) | <0·001 |
|
| 1·010 (1·007–1·014) | <0·001 | 1·011 (1·007–1·014) | <0·001 |
|
| ||||
| Nil | 1 | 1 | ||
| Transient filtration | 1·820 (1·558–2·127) | <0·001 | 1·914 (1·623–2·256) | <0·001 |
| Short-term dialysis | 2·225 (1·877–2·636) | <0·001 | 2·183 (1·823–2·614) | <0·001 |
| Long-term dialysis | 8·860 (5·243–14·973) | <0·001 | 7·518 (4·550–12·422) | <0·001 |
|
| 2·439 (2·171–2·739) | <0·001 | 2·427 (1·924–3·062) | <0·001 |
|
| 2·113 (1·569–2·846) | <0·001 | 1·654 (1·214–2·254) | 0·001 |
|
| 1·380 (1·232–1·544) | <0·001 | 1·152 (1·021–1·300) | 0·022 |
Values in parentheses are 95 per cent confidence intervals. These variables were selected using a backwards stepwise approach. RRT, renal replacement therapy; HA, hepatic artery.
Predictors of biliary leak and stricture in whole deceased donor liver transplants, using pooled data from all 20 imputed datasets (n = 7555)
| Simple logistic regression | Adjusted | |||
|---|---|---|---|---|
| Odds ratio | P |
| P | |
|
| ||||
| Recipient MELD | 1·02 (1·00–1·03) | 0·019 | 1·02 (1·00–1·03) | 0·023 |
| Vascular anastomosis time (per minute) | 1·01 (1·00–1·02) | 0·001 | 1·01 (1·00–1·02) | 0·001 |
| DCD graft (DBD as comparator) | 1·19 (0·93–1·52) | 0·168 | 1·42 (1·10–1·84) | 0·007 |
| Aberrant hepatic artery anatomy | 1·37 (1·05–1·78) | 0·020 | 1·37 (1·05–1·79) | 0·021 |
| Female donor | 1·22 (0·99–1·51) | 0·067 | 1·24 (1·00–1·54) | 0·047 |
| Biliary anastomosis | ||||
| CDCD | 1 | 1 | ||
| Roux | 1·28 (0·96–1·70) | 0·091 | 1·15 (0·84–1·58) | 0·394 |
| T-tube | 1·99 (1·21–3·28) | 0·007 | 2·06 (1·23–3·42) | 0·006 |
| Stent | 1·57 (0·37–6·63) | 0·536 | 1·54 (0·36–6·53) | 0·561 |
| Previous liver transplants | ||||
| 0 | 1 | 1 | ||
| 1 | 1·34 (0·94–1·92) | 0·104 | 1·21 (0·82–1·79) | 0·347 |
| 2 | 1·26 (0·51–3·12) | 0·624 | 1·12 (0·44–2·88) | 0·810 |
| ≥3 | 6·95 (1·87–25·79) | 0·004 | 6·07 (1·56–23·69) | 0·009 |
| Recipient ethnicity | ||||
| White | 1 | 1 | ||
| Asian | 0·64 (0·40–1·02) | 0·058 | 0·61 (0·38–0·97) | 0·038 |
| Black | 0·91 (0·48–1·74) | 0·783 | 0·85 (0·44–1·63) | 0·622 |
| Other | 0·60 (0·24–1·46) | 0·256 | 0·58 (0·24–1·43) | 0·236 |
|
| ||||
| DCD graft (DBD as comparator) | 1·37 (1·09–1·71) | 0·007 | 1·31 (1·04–1·64) | 0·022 |
| Biliary anastomosis | ||||
| CDCD | 1 | 1 | ||
| Roux | 0·54 (0·38–0·77) | 0·001 | 0·56 (0·39–0·80) | 0·001 |
| T-tube or stent | 0·71 (0·37–1·36) | 0·305 | 0·75 (0·39–1·44) | 0·390 |
Values in parentheses are 95 per cent confidence intervals. Odds ratios from simple and multiple binary logistic regression are given. These variables were selected using a backwards stepwise approach. MELD, model for end-stage liver disease; DCD, donation following circulatory death; DBD, donation following brainstem death; CDCD, choledocho-choledochostomy; Roux, Roux-en-Y hepaticojejunostomy.